Boston Scientific Corporation [BSX] is 4.76% higher this YTD. Is it still time to buy?

Boston Scientific Corporation [NYSE: BSX] jumped around 0.71 points on Tuesday, while shares priced at $44.50 at the close of the session, up 1.62%. The company report on November 29, 2022 that Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures.

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc. (Nasdaq: APEN) for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million.1.

Boston Scientific Corporation stock is now 4.76% up from its year-to-date (YTD) trading value. BSX Stock saw the intraday high of $44.645 and lowest of $43.84 per share. The company’s 52-week high price is 47.49, which means current price is +27.22% above from all time high which was touched on 04/20/22.

Compared to the average trading volume of 7.03M shares, BSX reached a trading volume of 5543851 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Boston Scientific Corporation [BSX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BSX shares is $48.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BSX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Barclays have made an estimate for Boston Scientific Corporation shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 18, 2022. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on October 12, 2022, representing the official price target for Boston Scientific Corporation stock. Previously, the target price had yet another raise to $43, while Wolfe Research analysts kept a Outperform rating on BSX stock.

The Average True Range (ATR) for Boston Scientific Corporation is set at 0.97, with the Price to Sales ratio for BSX stock in the period of the last 12 months amounting to 5.03. The Price to Book ratio for the last quarter was 3.61, with the Price to Cash per share for the same quarter was set at 0.24. Price to Free Cash Flow for BSX in the course of the last twelve months was 113.93 with Quick ratio for the last quarter at 0.90.

How has BSX stock performed recently?

Boston Scientific Corporation [BSX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.63. With this latest performance, BSX shares gained by 3.10% in over the last four-week period, additionally plugging by 8.51% over the last 6 months – not to mention a rise of 15.31% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BSX stock in for the last two-week period is set at 64.64, with the RSI for the last a single of trading hit 68.15, and the three-weeks RSI is set at 62.05 for Boston Scientific Corporation [BSX]. The present Moving Average for the last 50 days of trading for this stock 41.30, while it was recorded at 43.97 for the last single week of trading, and 41.18 for the last 200 days.

Boston Scientific Corporation [BSX]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Boston Scientific Corporation [BSX] shares currently have an operating margin of +16.17 and a Gross Margin at +62.76. Boston Scientific Corporation’s Net Margin is presently recorded at +8.75.

Return on Equity for this stock inclined to 6.51, with Return on Assets sitting at 3.30.

Boston Scientific Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.40.

Earnings analysis for Boston Scientific Corporation [BSX]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BSX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Boston Scientific Corporation go to 10.80%.

Insider trade positions for Boston Scientific Corporation [BSX]

There are presently around $58,414 million, or 94.60% of BSX stock, in the hands of institutional investors. The top three institutional holders of BSX stocks are: BLACKROCK INC. with ownership of 127,361,993, which is approximately 0.874% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 116,886,236 shares of the stock with an approximate value of $5.2 billion in BSX stocks shares; and MASSACHUSETTS FINANCIAL SERVICES CO /MA/, currently with $3.74 billion in BSX stock with ownership of nearly 0.581% of the company’s market capitalization.

Positions in Boston Scientific Corporation stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 418 institutional holders increased their position in Boston Scientific Corporation [NYSE:BSX] by around 57,943,827 shares. Additionally, 372 investors decreased positions by around 50,668,392 shares, while 154 investors held positions by with 1,204,066,972 shares. The mentioned changes placed institutional holdings at 1,312,679,191 shares, according to the latest SEC report filing. BSX stock had 80 new institutional investments in for a total of 6,142,137 shares, while 87 institutional investors sold positions of 19,503,996 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here